Revolutionary Genome-Editing Strategy to Treat Diverse Disorders

Nonsense mutations are genetic alterations in which a single incorrect DNA base introduces a premature stop codon (such as TAG) into the protein-coding sequence. During protein synthesis, ribosomes interpret this stop signal as the end of translation, resulting in a truncated and usually non-functional protein. Such mutations account for nearly 25% of known disease-causing genetic changes, contributing to conditions like cystic fibrosis, Batten disease, Tay-Sachs disease, and Niemann-Pick C1 disease.

The therapeutic challenge lies in the diversity of these mutations. Each nonsense mutation occurs at a different location within different genes, meaning traditional treatments must be gene-specific or even mutation-specific. This leads to a fragmented and expensive therapeutic landscape, where each disorder requires independent drug development, testing, and regulatory approval.

Therefore, nonsense mutations represent both a biological and policy challenge. Biologically, they interrupt essential protein production; economically, they demand customised therapies. A gene-agnostic strategy capable of addressing multiple nonsense mutations simultaneously would significantly transform rare disease treatment paradigms.

PERT is an innovative genome-editing approach that repurposes one of the cell’s own transfer RNA (tRNA) genes into a suppressor tRNA capable of overriding premature stop codons. Normally, tRNAs recognise specific codons in mRNA and deliver corresponding amino acids during protein synthesis. By using prime editing, researchers rewrote a non-essential tRNA gene so that it inserts an amino acid at the site of a premature stop signal instead of halting translation.

Prime editing relies on a specialised molecule called a prime-editing guide RNA (pegRNA), which directs the editing enzyme to a precise DNA location and provides the template for rewriting the sequence. Through screening over 17,000 pegRNA designs, researchers identified an efficient editing system (PE6c combined with PE3) that achieved 60–80% editing efficiency in cultured human cells — significantly higher than conventional homology-directed repair.

Importantly, PERT selectively ignores disease-causing premature stop codons while preserving natural stop signals. This specificity minimises global disruption of protein synthesis, making it a promising and safer gene-agnostic therapeutic strategy.

The primary advantage of PERT lies in its gene-agnostic design. Instead of targeting each disease-causing mutation individually, it modifies a redundant tRNA gene to suppress multiple premature stop codons. This could dramatically reduce the time and cost associated with developing separate therapies for rare diseases. Laboratory experiments restored 17–70% enzyme activity in cell models of Batten and Tay-Sachs diseases and showed measurable protein production in Niemann-Pick C1 models.

However, challenges remain. Effective delivery of genome-editing components into different tissues — especially the brain — is complex. Although AAV9 vectors restored 1.7–7% enzyme activity in Hurler syndrome mouse models, these levels, while beneficial, remain modest. Long-term safety, immune responses, and off-target effects also require extensive evaluation before human application.

Thus, while PERT represents a conceptual breakthrough, its translation to clinical practice depends on solving delivery, durability, and regulatory challenges. The promise is substantial, but cautious optimism is warranted.

In cell models of Batten and Tay-Sachs diseases, PERT restored enzyme activity to between 17% and 70% of normal levels, a range considered therapeutically meaningful in many lysosomal storage disorders. In Niemann-Pick C1 models, previously absent full-length protein production was partially restored. These results demonstrate that even modest restoration of enzyme function can significantly improve cellular pathology.

In vivo experiments in Hurler syndrome mouse models further validated the approach. Using AAV9 vectors to deliver editing components, researchers achieved 1.7–7% enzyme activity in key organs such as the brain, heart, and liver. Although seemingly low, such levels are known to reduce disease severity in similar metabolic disorders.

These findings suggest that PERT does not need to achieve complete correction to be clinically beneficial. The case also aligns with earlier successful base-editing treatments targeting TAG stop codons, indicating a viable translational pathway for similar gene-editing strategies.

Rare genetic diseases collectively affect millions worldwide, yet each individual condition impacts a small population. Developing separate therapies for each mutation is economically inefficient and often unattractive for pharmaceutical investment. A gene-agnostic therapy like PERT offers a scalable model that can potentially treat multiple disorders caused by a common mutation mechanism.

From a public health perspective, such an approach reduces research duplication and accelerates clinical translation. It also supports equitable access by lowering development costs and expanding applicability across diseases. This is particularly important in countries like India, where rare disease treatment affordability remains a concern.

Thus, gene-agnostic therapies represent not only a scientific innovation but also a policy innovation, potentially reshaping regulatory pathways, funding models, and health technology assessments for rare genetic conditions.

Earlier this year, the first reported clinical use of base editing targeted a TAG premature stop codon in an individual patient. This milestone demonstrated that gene-editing tools could be delivered safely into human tissues using viral vectors such as AAV. The success provided proof that precise genomic modifications can occur in vivo without catastrophic off-target effects.

PERT builds upon this precedent by offering a more universal mechanism to suppress TAG and potentially other stop codons. The existence of validated delivery platforms, such as AAV9, strengthens the translational feasibility of this approach. Moreover, regulatory agencies are gradually developing frameworks for evaluating gene-editing therapies, creating a clearer path to clinical trials.

Therefore, while PERT remains in preclinical stages, the success of related gene-editing interventions signals that its journey from laboratory to clinic is plausible, provided safety and long-term efficacy are demonstrated.